851 results on '"Martinelli, Giovanni"'
Search Results
2. Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series
3. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
4. A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications
5. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
6. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
7. Nilotinib : a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
8. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
9. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
10. Geochemical characteristics of natural springs within the Lenglongling fault zone related to the Menyuan Ms 6.9 earthquake on January 8, 2022, NW China
11. Earthquake geochemical scientific expedition and research
12. Personalizing precision medicine: Patients with AML perceptions about treatment decisions
13. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients
14. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
15. Notes for a History of Gas Geochemistry
16. Fall predictors in hospitalized patients living with cancer: a case–control study
17. Geochemical features and seismic imaging of the tectonic zone between the Tibetan Plateau and Ordos Block, central northern China
18. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
19. Heterogeneous self-tracked health and fitness data integration and sharing according to a linked open data approach
20. Effects of yoga practice on physiological distress, fatigue and QOL in patients affected by breast cancer undergoing adjuvant radiotherapy
21. Geochemical and geophysical effects of tectonic activity in faulted areas of the North China Craton
22. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
23. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
24. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
25. Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes
26. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
27. CometAnalyser: A user-friendly, open-source deep-learning microscopy tool for quantitative comet assay analysis
28. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
29. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
30. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
31. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
32. Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients
33. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
34. Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
35. Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis
36. Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.
37. Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches.
38. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients.
39. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
40. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
41. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
42. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer
43. Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome
44. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
45. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
46. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
47. MM-499 Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone
48. MM-501 Domestic Opportunity in Heavily Pretreated Multiple Myeloma Not Eligible for Hospital-Based Treatment: Role of Pomalidomide-Dexamethasone
49. MM-498 Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory Multiple Myeloma: Switching From Doublet to Triplet
50. MM-494 Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in Novel Agents' Era
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.